Key Takeaways HUM's growth is driven by Medicare Advantage expansion, strong retention and rising premiums.HUM is scaling CenterWell and boosting efficiency via automation and strategic acquisitions.HUM faces rising medical costs and higher debt, pressuring margins and operating leverage.Humana Inc. (HUM) benefits from a strong care delivery model centered on value-based care, increasing premiums, strategic acquisitions, an aging population in the United States and solid cash generation capacity. HUM’s shar ...

Core Viewpoint - Humana's recent earnings report indicates a mixed performance with a significant adjusted loss per share, despite revenue growth driven by its CenterWell unit, raising questions about future performance and investor sentiment [2][3][21]. Financial Performance - Humana reported a Q4 2025 adjusted loss of $3.96 per share, which was narrower than the consensus estimate of a loss of $4.01 per share but wider than the prior year's loss of $2.16 per share [2]. - Adjusted revenues increased by 11.8% year over year to $32.6 billion, surpassing the consensus mark by 2.4% [2]. - Premiums totaled $30.9 billion, up 11.3% year over year, exceeding both the consensus estimate of $30.2 billion and the internal estimate of $29.8 billion [4]. - Total operating expenses rose by 12% year over year to $33.3 billion, higher than the internal estimate of $31.8 billion [5]. Segment Performance - The Insurance segment's adjusted revenues increased by 11.3% year over year to $31.3 billion, driven by improved per-member premiums and an expanding customer base [6]. - CenterWell recorded revenues of $6 billion, a 16.2% year-over-year increase, benefiting from higher revenues in pharmacy and primary care businesses [8]. Membership and Operating Metrics - Total medical membership in the Insurance segment fell by 8.2% year over year to 15 million, below the consensus estimate of 15.1 million [7]. - The benefit ratio for the quarter was 93%, deteriorating by 150 basis points year over year [5]. Cash Flow and Capital Deployment - Humana ended Q4 with cash and cash equivalents of $4.2 billion, an increase of 89.1% from the end of 2024 [10]. - The company generated net cash from operations of $921 million in 2025, a decline of 68.9% from the previous year [11]. - Humana repurchased shares worth $151 million and paid dividends of $430 million during 2025 [12]. Full-Year and Future Outlook - For 2025, adjusted revenues reached $129.8 billion, a 10.7% year-over-year growth, while adjusted EPS rose by 5.7% to $17.14 [13]. - For 2026, revenues are projected to be at least $160 billion, indicating a 23.4% increase from 2025, with adjusted EPS expected to decline by 47.5% to at least $9.00 [14][15]. - Management anticipates growth in Individual Medicare Advantage membership by around 25% in 2026 [15]. Market Position and Competitor Performance - Humana's stock has seen a downward trend in estimates since the earnings release, with a Zacks Rank of 3 (Hold), suggesting an in-line return in the near term [21]. - In comparison, Molina, a competitor in the same industry, reported a revenue increase of 8.3% year over year, but has a Zacks Rank of 5 (Strong Sell) due to negative estimate revisions [22][23].

Core Insights - A study by Humana Healthcare Research and Yale School of Medicine indicates a significant increase in continuous glucose monitor (CGM) usage among Medicare Advantage members with type 2 diabetes from 2021 to 2023 [1] - The study highlights that CGM users often have more complex health issues compared to non-users, emphasizing the need for further research on clinical outcomes and patient access [1] Group 1: Study Findings - The proportion of Medicare Advantage members with type 2 diabetes using insulin and CGMs rose from less than 2% in January 2021 to approximately 16% by December 2023 [1] - Patients with fewer healthcare interactions and those in the oldest age group were less likely to use CGMs [1] - Patients who had an endocrinology visit in the past year were over four times more likely to use a CGM device [1] Group 2: Implications and Coverage - The growth in CGM adoption coincided with the expansion of Medicare coverage for these devices in 2023 [1] - By 2026, most individuals with a Humana Medicare Advantage plan will have access to CGMs at no out-of-pocket cost, as these devices will be fully covered [1] - The research aims to identify which patients may benefit most from CGMs, particularly those who do not frequently visit doctors, to improve health outcomes [1]

Industry Overview - The U.S. health insurance industry, known as Health Maintenance Organization (HMO), is focusing on technological innovation and pursuing mergers and acquisitions (M&A) to enhance capabilities and expand market presence [1][7] - The industry is experiencing rising medical expenses due to deferred care, chronic disease management, and increasing costs of specialty drugs [2][4] - The HMO industry consists of entities that provide basic and supplemental health services, assuming risks and assigning premiums to health insurance policies [3] Trends Impacting the Industry - Escalating medical expenses are driven by delayed medical procedures, increased demand for screenings, and a growing aging population, which is straining the Health Benefit Ratio and profit margins [4] - Regulatory changes, including the One Big Beautiful Bill Act, may tighten Medicaid eligibility and reduce ACA enrollment, impacting membership and reimbursements [5] - A nationwide shortage of healthcare professionals is affecting hospital operations and the quality of care, which could impact customer retention for HMOs [6] Strategic Initiatives - HMOs are increasingly focusing on M&A to broaden capabilities, enter new markets, and enhance their competitive advantage [7][8] - The Federal Reserve's interest rate cuts in 2025 are expected to lower borrowing costs, potentially fueling M&A activity in the industry [8] Industry Performance - The Zacks Medical-HMO industry has underperformed, declining 35.6% over the past year compared to the S&P 500's growth of 24.4% [12] - The industry's current valuation is at a forward P/E ratio of 13.71X, significantly lower than the S&P 500's 22.01X and the sector's 20.66X [15] Company Highlights - **UnitedHealth Group**: Revenue growth is supported by strong performance in its UnitedHealthcare and Optum segments, with a 2026 earnings estimate of $17.70 per share, indicating 8.3% growth [20][21] - **Cigna**: Thrives on the performance of its Evernorth and Cigna Healthcare platforms, with a 2026 earnings estimate of $30.29 per share, reflecting 1.5% growth [24][25] - **Humana**: Achieves consistent growth through higher premium revenues and a strong membership base, with a 2026 earnings estimate of $9.82 per share, indicating significant growth potential [29][30] - **Centene**: Revenue growth is driven by its Medicare and Medicaid businesses, with a 2026 earnings estimate of $3.01 per share, suggesting a 44.7% rise from the previous year [33][34]

Core Themes - The company remains committed to achieving a stable and compelling margin of at least 3% for Medicare and aims to restore its earnings power by 2028 [2] Adjustments to Environment - The company acknowledges the need to make adjustments in response to the current medical cost trend and rate environment, which may involve modifying benefits to align with funding and medical cost considerations [3]

Humana (NYSE:HUM) 2026 Conference Summary Company Overview - **Company**: Humana Inc. - **Industry**: Healthcare and Medicare Advantage Key Themes and Commitments - Humana reaffirmed its commitment to achieving a stable Medicare Advantage (MA) margin of at least 3% and restoring earnings power by 2028, as stated during the Investor Day in June 2025 [2][3] - Adjustments to benefits will be necessary to accommodate the current medical cost trends and funding environment [3][12] Lifetime Value of Members - The concept of lifetime value is emphasized, indicating that the economic value of a member increases significantly from year one to year two, primarily due to lower retention costs and better member management [3][4] - A stable MA margin is essential for maximizing member retention and minimizing attrition [4][5] Membership Metrics - During the Annual Enrollment Period (AEP), over 1 million new members were added, with approximately 70% being switchers from other plans, which are generally more economically favorable in the first year [17][18] - Humana absorbed about 12% of plan exits, indicating a positive mix of new members coming from other plans rather than exits [18][19] - 70% of new members are enrolled in four-star or better contracts, and 75% are acquired through higher-quality sales channels [18][19] Sales Channel Strategy - Humana has focused on improving the quality of its sales channels by trimming lower-performing call centers and broker partners, which has led to a better membership mix [22] Margin Profiles and Member Engagement - The company expects to double margins despite headwinds from Star ratings, with a consistent mix of HMO and PPO plans compared to previous years [23][26] - Engagement initiatives have been enhanced, with proactive outreach to new members to improve their onboarding experience and overall satisfaction [54][56] Star Ratings and Operational Performance - Humana is optimistic about its Star Ratings performance, having made significant strides in operational metrics and member engagement [63][64] - Recent changes proposed by CMS to focus more on health outcomes rather than administrative metrics are supported by Humana, as they align with the company's ongoing efforts to improve quality [70][71] Part D and PDP Margins - Humana is guiding towards break-even margins for its Part D business, with expectations for more consistent profitability as the program stabilizes [72][74] - The company views its PDP as a strategic starter product that can lead to further engagement in MAPD plans [75] Regulatory Environment and Rate Notice - The company expressed concerns about the implications of the preliminary rate notice from CMS, emphasizing the need for adjustments to maintain benefits amidst rising costs [80][81] - Humana is actively engaging with policymakers to advocate for necessary changes that would benefit members [81] CenterWell and Acquisitions - Recent acquisitions in Florida are aimed at filling geographic gaps in Humana's CenterWell portfolio, enhancing operational fit and expanding the primary care footprint [102][103] - The company emphasizes that both the Medicare Advantage and CenterWell businesses must stand alone financially [106] Conclusion - Humana is strategically positioned to navigate the current healthcare landscape, focusing on member retention, quality improvement, and operational efficiency while adapting to regulatory changes and market dynamics. The company remains committed to its long-term financial goals and enhancing member value through targeted initiatives.

Core Viewpoint - Humana Inc. has successfully completed a public offering of $1.0 billion in junior subordinated notes, which will mature in 2056 and carry a fixed interest rate of 6.625 percent [1] Group 1: Offering Details - The total principal amount of the junior subordinated notes offering is $1.0 billion [1] - The expected net proceeds from the offering are approximately $986 million after accounting for underwriters' discounts and estimated offering expenses [1]

Company Overview - Humana Inc. (HUM) is headquartered in Louisville, Kentucky, and provides medical and specialty insurance products with a market cap of $21.6 billion [1] - The company offers coordinated health care through health maintenance organizations, point-of-service plans, and administrative services products [1] Market Position - HUM is classified as a large-cap stock, underscoring its size, influence, and dominance within the healthcare plans industry [2] - The company leads the Medicare Advantage sector with a substantial customer base and competitive edge, driven by a focused strategy [2] - Humana has diversified into healthcare services, including primary care and pharmacy benefit management, capturing more value in the healthcare chain [2] Stock Performance - HUM has experienced a significant decline, slipping 43.2% from its 52-week high of $315.35, achieved on September 5, 2025 [3] - Over the past three months, HUM stock declined 30.5%, underperforming the S&P 500 Index's 1.9% decline during the same period [3] - Year-to-date, shares of HUM fell 30.1% and dipped 32.6% over the past 52 weeks, notably underperforming the S&P 500's YTD 1.5% losses and 17.5% returns over the last year [3] Technical Indicators - HUM has been trading below its 50-day and 200-day moving averages since late January, confirming a bearish trend [4] Financial Results - In Q4, HUM reported an adjusted loss of $3.96 per share, which beat Wall Street expectations of $4.01 per share [5] - The company's adjusted revenue was $32.6 billion, surpassing Wall Street forecasts of $31.9 billion [5] - HUM expects full-year adjusted EPS to be $9 [5] Competitive Landscape - The Cigna Group (CI) has taken the lead over HUM in the competitive healthcare plans arena, showing resilience with a 1.3% loss on a YTD basis [6] - Wall Street analysts maintain a consensus "Moderate Buy" rating for HUM, with a mean price target of $219.13, suggesting a potential upside of 22.3% from current price levels [6]

Core Viewpoint - AM Best has assigned a Long-Term Issue Credit Rating of "bbb-" (Good) to Humana Inc.'s $1 billion, 6.625% fixed rate junior subordinated notes, due 2056, with a stable outlook [1] Group 1 - The proceeds from the issuance of the junior subordinated notes will be used for general corporate purposes [1]

Core Viewpoint - Humana Inc. has announced a public offering of $1.0 billion in junior subordinated notes, which are set to close on March 9, 2026, pending customary closing conditions [1]. Group 1 - The offering consists of fixed-to-fixed rate junior subordinated notes due in 2056, priced at 100.000 percent of the principal amount [1]. - The company anticipates net proceeds from the offering, although specific figures for the net proceeds are not disclosed [1].